Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab and GlaxoSmithKline (GSK) have announced the submission of a new drug application (NDA) for Arzerra (ofatumumab) to the Japanese Ministry of Health, Labor and Welfare (MHLW).
Subscribe to our email newsletter
Arzerra (ofatumumab) is submitted for the approval to treat chronic lymphocytic leukemia (CLL).
Genmab chief executive officer Jan van de Winkel said, "This marks another important achievement in our collaboration with GSK for Arzerra."
Genmab is a publicly traded, biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.